VENTURE LIFE GROUP PLC - Interim Results for the 12 month period ending 31 December 2025

Venture Life Group PLC’s (VLG:AIM) 2025 investor update highlights a major strategic transformation, with the company emerging as a simplified, higher-margin, pure-play consumer healthcare business following the divestment of its CDMO operations and selected oral care brands. The group reported pro forma revenue growth of 11.4% to £35 million, driven primarily by volume, while its four core power brands delivered 15% growth and strong UK momentum. Gross profit increased to £15.8 million, with stable gross margins, while EBITDA remained broadly flat at £6.0 million as the business deliberately increased marketing investment and strengthened digital, innovation and leadership capabilities to support future scale. Venture Life ended 2025 with a robust £34 million net cash position and no debt, providing significant flexibility for value-enhancing M&A, share buybacks and continued investment in growth strategy. Management highlighted strong early 2026 trading, with revenue up 18% year on year and margin improvement supported by premium new product launches, higher-margin innovation and improved pricing. Key growth drivers include the Health & Her and Health & Him brands, Balance Activ, Lift and Earol, alongside expanding international partnerships and a growing order book of product innovation across women’s health, men’s health and longevity. Overall, the presentation reinforces confidence in Venture Life’s financial results, cash generation, brand performance, EBITDA potential and long-term growth strategy as it targets scalable, profitable growth in consumer healthcare.